The report provides a detailed analysis essential for establishing a conivaptan production plant. It encompasses all critical aspects necessary for conivaptan production, including the cost of conivaptan production, conivaptan plant cost, conivaptan production costs, and the overall conivaptan production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a conivaptan production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Conivaptan is a prescription medication mainly used in hospitals to help manage low sodium levels (hyponatraemia) in the blood, especially when the imbalance becomes serious. It works by blocking certain receptors that control how the body handles water, which helps remove extra fluid without losing important salts. It is prescribed for the treatment of low sodium levels in the blood, which is a condition known as hyponatraemia caused by the syndrome of inappropriate antidiuretic hormone (SIADH). It is primarily given to patients whose sodium imbalance is linked to conditions such as heart failure or a syndrome that affects hormone balance. It finds its main application in the short-term management of serious sodium imbalance in hospitalised patients. Moreover, it is administered through intravenous infusion under close medical supervision to ensure safe and controlled correction of sodium levels. It is used in hospital settings to stabilise patients so they can respond better to care and regain normal fluid balance.
The primary factor that drives the demand for conivaptan is its application as an intravenous drug to help manage low sodium levels in the blood, which supports its market growth. Its application as a vasopressin antagonist for the treatment of euvolemic and hypervolemic hyponatraemia in hospitalised patients largely drives its demand in the pharmaceutical industry. Its usage as a medication in patients with heart failure or hormone-related issues that cause fluid buildup also contributes to its demand in the medical and pharmaceutical industries.
Its demand in critical care settings, where careful fluid and electrolyte management is required, also supports its market expansion. Advancements in injectable drug production, dependable supplier partnerships, and well-managed cold chain and hospital distribution networks also play an important role in shaping the global supply and procurement decisions for conivaptan. Additionally, industrial conivaptan procurement also depends on factors such as the cost and availability of active pharmaceutical ingredients, strict regulatory approvals, quality compliance standards, and controlled production requirements.
Raw Material for Conivaptan Production
According to the conivaptan production plant project report, the major raw materials for conivaptan production include benzazepinone, pyridinium hydrobromide perbromide, ethaneimidate hydrochloride, biphenyl benzoic acid, aminobenzoic acid, and imidazo benzazepine.
Production Process of Conivaptan
The extensive conivaptan production cost report consists of the following industrial production process:
- Production via Bromination and Coupling Reaction: The production process of conivaptan hydrochloride begins with the bromination of a benzazepinone intermediate using pyridinium hydrobromide perbromide to form a brominated compound, which is purified by recrystallisation. Then, this bromide is reacted with ethaneimidate hydrochloride in the presence of a base to build the imidazole ring, which gives the sulfonamide intermediate. The tosyl protecting group is removed by heating in sulfuric acid, and the resulting imidazo benzazepine is isolated by crystallisation. In parallel, the required acid coupling partner is prepared from biphenyl benzoic acid through conversion to the acid chloride and further coupling with aminobenzoic acid, followed by purification. The acid is again converted to its acid chloride and coupled with the imidazo benzazepine intermediate, and after recrystallisation in acidic ethanol, conivaptan hydrochloride is obtained as the final product.
Conivaptan is a non-peptide, dual antagonist of arginine vasopressin (AVP) V1A and V2 receptors, and it acts as an antidiuretic hormone inhibitor. It appears as a white to off-white or pale orange-white powder in its hydrochloride salt form. The molecular formula of the compound is C32H26N4O2, and its molar mass is 498.57 g/mol. The compound is very slightly soluble in water, with a solubility of approximately 0.15 mg/mL at 23 degrees Celsius, and it has a flash point of 408.1 degrees Celsius. It is generally marketed under the brand name Vaprisol. The compound is a potent inhibitor of CYP3A4 and should be stored at 2–8 degrees Celsius. It is recommended to wear protective clothing like gloves and a mask while handling the compound. Extended exposure to this substance or improper use may cause serious adverse effects such as injection site reactions, hypotension, and hypokalemia. There is also a risk of overly rapid correction of serum sodium, which can lead to osmotic demyelination syndrome.
